Long-term administration of beraprost sodium for pulmonary arterial hypertension associated with congenital heart disease.
Pulmonary arterial hypertension (PAH) is often associated with congenital heart disease (CHD). Acute administration of beraprost reduces pulmonary vascular resistance in patients with idiopathic PAH and PAH associated with CHD; however, little is known about whether or not long-term treatment with oral beraprost benefits these patients. We report the case of a patient suffering from severe PAH associated with large patent ductus arteriosus (PDA), who was considered to be ineligible for PDA closure using a conventional treatment strategy. Eventually, long-term administration of oral beraprost ameliorated the degree of PAH and the patient subsequently underwent successful closure of the PDA.
Oyamada
Jun
J
Pediatrics, Reproductive and Developmental Medicine, Akita University, Akita. jun@doc.med.akita-u.ac.jp
Toyono
Manatomo
M
Shimada
Shunsuke
S
Aoki-Okazaki
Mieko
M
Tamura
Masamichi
M
Takahashi
Tsutomu
T
D002675:Child, Preschool; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D008297:Male
C048081:beraprost; D011464:Epoprostenol